PL374598A1 - Inhibitory kaspazy i ich zastosowania - Google Patents

Inhibitory kaspazy i ich zastosowania

Info

Publication number: PL374598A1
Authority: PL; Poland
Prior art keywords: caspase inhibitors; caspase; inhibitors
Prior art date: 2002-06-28

Application number

PL03374598A

Other languages

English (en)

Inventor

Ronald Knegtel

Michael Mortimore

John Studley

David Millan

Original Assignee

Vertex Pharmaceuticals Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-28

Filing date

2003-06-27

Publication date

2005-10-31

2003-06-27 Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated

2005-10-31 Publication of PL374598A1 publication Critical patent/PL374598A1/pl

Links

102000011727 Caspases Human genes 0.000 title 1
108010076667 Caspases Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
AIDS & HIV (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Tropical Medicine & Parasitology (AREA)

PL03374598A 2002-06-28 2003-06-27 Inhibitory kaspazy i ich zastosowania PL374598A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US39259202P	2002-06-28	2002-06-28
US43507302P	2002-12-20	2002-12-20

Publications (1)

Publication Number	Publication Date
PL374598A1 true PL374598A1 (pl)	2005-10-31

Family

ID=30003264

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03374598A PL374598A1 (pl)	2002-06-28	2003-06-27	Inhibitory kaspazy i ich zastosowania

Country Status (19)

Country	Link
US (2)	US7553852B2 (pl)
EP (1)	EP1539701A1 (pl)
JP (2)	JP4616643B2 (pl)
KR (1)	KR20050013260A (pl)
CN (1)	CN100503572C (pl)
AR (1)	AR040350A1 (pl)
AU (1)	AU2003248758A1 (pl)
BR (1)	BR0312232A (pl)
CA (1)	CA2493646A1 (pl)
IL (1)	IL165986A0 (pl)
MX (1)	MXPA05000069A (pl)
NO (1)	NO20050851L (pl)
NZ (1)	NZ537807A (pl)
PE (1)	PE20040728A1 (pl)
PL (1)	PL374598A1 (pl)
RU (1)	RU2005102094A (pl)
TW (1)	TW200404783A (pl)
UY (1)	UY27872A1 (pl)
WO (1)	WO2004002961A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20011350A1 (es)	2000-05-19	2002-01-15	Vertex Pharma	PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
PL374598A1 (pl)	2002-06-28	2005-10-31	Vertex Pharmaceuticals Incorporated	Inhibitory kaspazy i ich zastosowania
US7612091B2 (en)	2002-12-20	2009-11-03	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
PE20050159A1 (es) *	2003-05-27	2005-04-19	Vertex Pharma	Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
EP2399916B1 (en) *	2004-03-12	2014-12-10	Vertex Pharmaceuticals Incorporated	Process and intermediates for the preparation of aspartic acetal caspase ihnhibitors
WO2005115362A1 (en) *	2004-05-15	2005-12-08	Vertex Pharmaceuticals Incorporated	Treating seizures using ice inhibitors
CA2567080A1 (en)	2004-05-27	2005-12-15	Vertex Pharmaceuticals Incorporated	Ice inhibitors for the treatment of autoinflammatory diseases
EP3121176A1 (en) *	2004-06-08	2017-01-25	Families of Spinal Muscular Atrophy	2,4-diaminoquinazolines for the treatment of spinal muscular atrophy
EP1784390A2 (en) *	2004-08-13	2007-05-16	Amgen Inc.	Substituted benzofused heterocycles
EP1791535B1 (en)	2004-09-17	2008-07-30	BioMAS Ltd.	Novel tellurium compounds and their use as immunomodulators
ATE543803T1 (de) *	2004-11-24	2012-02-15	Vertex Pharma	3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
EP1833803A4 (en) *	2005-01-03	2009-08-05	Myriad Genetics Inc	PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCTORS OF APOPTOSIS AND THEIR USE
US8258159B2 (en) *	2005-06-07	2012-09-04	The Trustees Of The University Of Pennsylvania	Inhibitors of the α2β1/GPIa-IIa integrin
US8987306B2 (en) *	2005-06-07	2015-03-24	The Trustees Of The University Of Pennsylvania	Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
CN101268084A (zh) *	2005-07-28	2008-09-17	沃泰克斯药物股份有限公司	天冬氨酸特异性半胱氨酸蛋白酶抑制剂前体药物
WO2007027742A2 (en) *	2005-08-31	2007-03-08	The Trustees Of The University Of Pennsylvania	SMALL MOLECULE INTEGRIN α2βl/GPIa-IIa ANTAGONISTS
EP2615086A1 (en)	2006-08-01	2013-07-17	Families of Spinal Muscular Atrophy	2,4-Diaminoquinazolines for the treatment of spinal muscular atrophy
EP2066640B1 (en) *	2006-09-11	2011-09-07	N.V. Organon	2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives
WO2008073388A2 (en) *	2006-12-11	2008-06-19	Mutual Pharmaceutical Company, Inc.	Alfuzosin formulations, methods of making and methods of use
US20100092556A1 (en) *	2006-12-11	2010-04-15	Kristin Arnold	Alfuzosin formulations, methods of making, and methods of use
FR2923160B1 (fr)	2007-11-02	2013-07-26	Pasteur Institut	Composes destines a prevenir ou traiter une infection virale.
WO2012061786A1 (en)	2010-11-05	2012-05-10	Brandeis University	Ice cleaved alpha-synuclein a biomarker
US9956260B1 (en)	2011-07-22	2018-05-01	The J. David Gladstone Institutes	Treatment of HIV-1 infection and AIDS
PL2809322T3 (pl) *	2012-01-26	2019-11-29	Ptc Therapeutics Inc	Związki do leczenia zaniku mięśni pochodzenia rdzeniowego
JP2017515854A (ja)	2014-05-12	2017-06-15	クオナトウスファーマシューティカルズ，インコーポレイテッド	カスパーゼ阻害剤による慢性肝疾患の合併症の治療
WO2017079566A1 (en)	2015-11-05	2017-05-11	Conatus Pharmaceuticals, Inc.	Caspase inhibitors for use in the treatment of liver cancer
CA3010286A1 (en)	2015-12-31	2017-07-06	Conatus Pharmaceuticals Inc.	Methods of using caspase inhibitors in treatment of liver disease
RU2019113150A (ru)	2016-10-05	2020-11-06	Новартис Аг	Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения
ES2988904T3 (es) *	2019-03-07	2024-11-22	Nobo Medicine Inc	Inhibidores de caspasa y métodos de utilización de los mismos
WO2022123062A1 (en)	2020-12-11	2022-06-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients
KR102670554B1 (ko) *	2022-01-04	2024-05-30	주식회사 이노보테라퓨틱스	캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6204261B1 (en)	1995-12-20	2001-03-20	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β Converting enzyme inhibitors
DD232699A1 (de)	1983-11-18	1986-02-05	Adw Ddr	Verfahren zur herstellung von chinazolin-4-on-3-alkansaeuren und deren estern
FR2582514B1 (fr)	1985-05-30	1988-02-19	Rhone Poulenc Sante	Medicaments a base d'amides, nouveaux amides et leur preparation
US5714484A (en)	1993-12-08	1998-02-03	Prototek, Inc.	α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
US5847135A (en)	1994-06-17	1998-12-08	Vertex Pharmaceuticals, Incorporated	Inhibitors of interleukin-1β converting enzyme
US5716929A (en)	1994-06-17	1998-02-10	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1β converting enzyme
US5756466A (en)	1994-06-17	1998-05-26	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en)	1995-06-05	2002-07-16	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β converting enzyme
EP0761680A3 (en)	1995-09-12	1999-05-06	Ono Pharmaceutical Co., Ltd.	Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
AU738341B2 (en)	1996-10-11	2001-09-13	Abbott Gmbh & Co. Kg	Asparate ester inhibitors of interleukin-1beta converting enzyme
CA2268086A1 (en)	1996-10-11	1998-04-23	Warner-Lambert Company	Sulfonamide interleukin-1.beta. converting enzyme inhibitors
US6063794A (en)	1996-10-11	2000-05-16	Cor Therapeutics Inc.	Selective factor Xa inhibitors
WO1998018781A2 (en)	1996-10-28	1998-05-07	Versicor, Inc.	Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
US6972296B2 (en)	1999-05-07	2005-12-06	Encysive Pharmaceuticals Inc.	Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
ATE383153T1 (de)	1999-05-07	2008-01-15	Encysive Pharmaceuticals Inc	Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
RU2255933C9 (ru)	1999-05-07	2005-11-20	Тексэс Байотекнолоджи Копэрейшн	ПРОИЗВОДНЫЕ ПРОПИОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА
AR026748A1 (es)	1999-12-08	2003-02-26	Vertex Pharma	Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
WO2001094351A1 (en)	2000-06-07	2001-12-13	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
JP2005509028A (ja)	2001-10-09	2005-04-07	バーテックスファーマシューティカルズインコーポレイテッド	アスパラギン酸およびグルタミン酸誘導体ならびにそのジアゾケトン中間体を合成するための方法
US7410956B2 (en)	2002-02-11	2008-08-12	Vertex Pharmaceuticals Incorporated	Caspase inhibitor prodrugs
AU2003225088A1 (en)	2002-04-19	2003-11-03	Vertex Pharmaceuticals Incorporated	Regulation of tnf-alpha
PL374598A1 (pl)	2002-06-28	2005-10-31	Vertex Pharmaceuticals Incorporated	Inhibitory kaspazy i ich zastosowania
US7612091B2 (en)	2002-12-20	2009-11-03	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
PE20050159A1 (es)	2003-05-27	2005-04-19	Vertex Pharma	Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
ATE543803T1 (de)	2004-11-24	2012-02-15	Vertex Pharma	3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren

2003
- 2003-06-27 PL PL03374598A patent/PL374598A1/pl not_active Application Discontinuation
- 2003-06-27 BR BR0312232-8A patent/BR0312232A/pt not_active IP Right Cessation
- 2003-06-27 MX MXPA05000069A patent/MXPA05000069A/es unknown
- 2003-06-27 CN CNB038187930A patent/CN100503572C/zh not_active Expired - Fee Related
- 2003-06-27 RU RU2005102094/04A patent/RU2005102094A/ru unknown
- 2003-06-27 JP JP2004518103A patent/JP4616643B2/ja not_active Expired - Fee Related
- 2003-06-27 CA CA002493646A patent/CA2493646A1/en not_active Abandoned
- 2003-06-27 AR ARP030102352A patent/AR040350A1/es unknown
- 2003-06-27 WO PCT/US2003/020557 patent/WO2004002961A1/en not_active Ceased
- 2003-06-27 PE PE2003000653A patent/PE20040728A1/es not_active Application Discontinuation
- 2003-06-27 KR KR10-2004-7021300A patent/KR20050013260A/ko not_active Ceased
- 2003-06-27 IL IL16598603A patent/IL165986A0/xx unknown
- 2003-06-27 US US10/609,147 patent/US7553852B2/en not_active Expired - Fee Related
- 2003-06-27 TW TW092117681A patent/TW200404783A/zh unknown
- 2003-06-27 NZ NZ537807A patent/NZ537807A/en unknown
- 2003-06-27 EP EP03762231A patent/EP1539701A1/en not_active Withdrawn
- 2003-06-27 AU AU2003248758A patent/AU2003248758A1/en not_active Abandoned
- 2003-06-30 UY UY27872A patent/UY27872A1/es unknown
2005
- 2005-02-17 NO NO20050851A patent/NO20050851L/no not_active Application Discontinuation
2009
- 2009-05-12 US US12/464,380 patent/US8129381B2/en not_active Expired - Fee Related
2010
- 2010-02-04 JP JP2010023632A patent/JP2010143942A/ja active Pending

Also Published As

Publication number	Publication date
CN100503572C (zh)	2009-06-24
RU2005102094A (ru)	2006-02-27
PE20040728A1 (es)	2004-10-23
US20090281128A1 (en)	2009-11-12
JP4616643B2 (ja)	2011-01-19
NZ537807A (en)	2007-05-31
US8129381B2 (en)	2012-03-06
CA2493646A1 (en)	2004-01-08
JP2010143942A (ja)	2010-07-01
JP2005533825A (ja)	2005-11-10
KR20050013260A (ko)	2005-02-03
US7553852B2 (en)	2009-06-30
NO20050851L (no)	2005-03-29
UY27872A1 (es)	2003-12-31
TW200404783A (en)	2004-04-01
BR0312232A (pt)	2005-05-10
EP1539701A1 (en)	2005-06-15
CN1675184A (zh)	2005-09-28
IL165986A0 (en)	2006-01-15
AU2003248758A1 (en)	2004-01-19
AR040350A1 (es)	2005-03-30
MXPA05000069A (es)	2005-04-11
US20040072850A1 (en)	2004-04-15
WO2004002961A1 (en)	2004-01-08

Legal Events

Date	Code	Title	Description
2013-02-28	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
PL374598A1 (pl)	2005-10-31	Inhibitory kaspazy i ich zastosowania
ZA200509700B (en)	2007-03-28	Caspase inhibitors and uses thereof
EP1539941A4 (en)	2006-11-29	ADZYMES AND THEIR USES
PL357713A1 (pl)	2004-07-26	Inhibitory kaspaz i ich zastosowania
TWI318207B (en)	2009-12-11	Carbamate caspase inhibitors and uses thereof
IL166377A0 (en)	2006-01-16	Vrgfr-2 and vgefr-3 inhibitory and anthranylamidpyrimidines
AU2003282478A8 (en)	2004-05-04	Discount-instrument methods and systems
GB0220214D0 (en)	2002-10-09	Compounds and their use
SI1551805T1 (sl)	2013-07-31	Substituirani gama-fenil-delta-laktami in njihova uporaba
IL177709A0 (en)	2006-12-31	Caspase inhibitors and uses thereof
IL165112A0 (en)	2005-12-18	Variant integrinpolypeptides and thereof
AU2003251513A8 (en)	2003-12-31	Rsk inhibitors and therapeutic uses thereof
AU2003231827A8 (en)	2003-12-12	Pseudo-tissues and uses thereof
AU2003302173A8 (en)	2004-07-14	Spirotetrathiocarbamates and spirooxothiocarbamates
GB0227906D0 (en)	2003-01-08	Compounds and their use
GB0220776D0 (en)	2002-10-16	FOXP2 and uses thereof
AU2003267790A8 (en)	2004-04-19	Lipase inhibitors and uses thereof
ZA200500776B (en)	2006-09-27	Caspase inhibitors and uses thereof
GB0230134D0 (en)	2003-01-29	Compounds and their use
AU2003216442A8 (en)	2003-09-09	Enkurin and uses thereof
GB0230281D0 (en)	2003-02-05	Compounds and their use
GB0317864D0 (en)	2003-09-03	Compounds and their use
EP1499338A4 (en)	2008-06-18	7-HYDROXY-16ALPHA-FLUORO-5-ANDROSENES-17-ONE AND 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTAN-17-ONE AND THEIR DERIVATIVES
GB0220215D0 (en)	2002-10-09	Compounds and their use
GB0213498D0 (en)	2002-07-24	Deoxyhypusine-synthase inhibitors pharmaceuticals comprising said inhibitors and uses thereof